Riskpilot← Back to searchSign inGet full accessEXPRES2ION BIOTECHNOLOGIES ApS
APSActiveCVR 32770487Agern Alle 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 201021 employeeshttp://www.expres2ionbio.com
Revenue 2024
DKK -24M
-38% vs 2023
EBITDA margin
164.6%
+38% vs 2023
Equity ratio
56.6%
Financial strength
Net profit 2024
DKK -19,8M
+64% vs 2023
| Revenue | DKK -24M | -38% |
| EBITDA | DKK -39,6M | +38% |
| Net profit | DKK -19,8M | +64% |
| Total assets | DKK 58M | +15% |
| Equity | DKK 32,8M | -22% |
| Employees | 21 | — |
Legal name
EXPRES2ION BIOTECHNOLOGIES ApS
CVR number
32770487
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. januar 2010
Share capital
DKK 530.835
Employees
21 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør eller af en direktør i forening med et bestyrelsesmedlem eller af den samlede bestyrelse
Company purpose
Selskabets formål er at drive virksomhed indenfor bioteknologi
Address
Agern Alle 1
Phone
+4522221019
Email
info@expres2ionbio.com
Website
http://www.expres2ionbio.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.617 | 5.662 | 5.342 | -2.240 | -494 | 2.507 | 510 | 2.814 | -7.044 | -7.806 | -57.917 | -38.920 | -24.035 |
| Staff expenses | -3.532 | -4.935 | -4.761 | -4.725 | -6.964 | -7.820 | -9.337 | -10.853 | -11.157 | -21.384 | -25.888 | -24.962 | -15.516 |
| EBITDA | -1.916 | 726 | 580 | -6.965 | -7.457 | -5.313 | -8.827 | -8.040 | -18.201 | -29.196 | -83.805 | -63.882 | -39.552 |
| Depreciation & amort. | -55 | -129 | -308 | -302 | -225 | -209 | -348 | -476 | -521 | -595 | -539 | -728 | -759 |
| EBIT | -1.970 | 597 | 273 | -7.266 | -7.682 | -5.522 | -9.175 | -8.516 | -18.722 | -29.791 | -84.344 | -64.611 | -40.311 |
| Net financials | 6 | -12 | -47 | -335 | -397 | -678 | -1.806 | -1.506 | -1.684 | 58 | -305 | 3.480 | 14.980 |
| Profit before tax | -1.965 | 585 | 226 | -7.601 | -8.080 | -6.200 | -10.981 | -10.022 | -20.406 | -29.733 | -84.649 | -61.130 | -25.331 |
| Tax | -185 | -0 | -0 | -857 | -959 | -1.068 | -1.229 | -1.411 | -2.041 | -2.508 | -5.500 | -5.501 | -5.500 |
| Net profit | -1.780 | 585 | 226 | -6.745 | -7.120 | -5.132 | -9.752 | -8.611 | -18.365 | -27.225 | -79.149 | -55.629 | -19.831 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.824 | 3.426 | 4.289 | 3.343 | 7.580 | 5.095 | 5.055 | 7.782 | 81.750 | 106.379 | 91.017 | 50.210 | 57.974 |
| Equity | 1.026 | 1.611 | 1.837 | -4.908 | 551 | -4.581 | -14.333 | -3.684 | 64.350 | 97.268 | 68.532 | 41.931 | 32.798 |
| Long-term debt | 0 | 0 | 0 | 4.505 | 4.295 | 4.775 | 4.958 | 5.585 | 5.814 | 2.511 | 1.338 | 965 | 935 |
| Short-term debt | 798 | 1.815 | 2.453 | 3.746 | 2.734 | 4.901 | 14.431 | 5.881 | 11.586 | 6.600 | 21.148 | 7.314 | 24.241 |
| Total debt | 798 | 1.815 | 2.453 | 8.251 | 7.030 | 9.677 | 19.388 | 11.466 | 17.401 | 9.111 | 22.485 | 8.279 | 25.175 |
EBITDA margin
-3955162700.0%
This company
15.8%
Market median
-25032675416% vs market
20122024
Equity ratio
56.6%
This company
38.2%
Market median
+48% vs market
20122024
Return on equity
-60.5%
This company
18.4%
Market median
-429% vs market
20122024
Net profit margin
-1983053500.0%
This company
8.1%
Market median
-24482142075% vs market
20122024
Asset turnover
-0.41×
This company
1.12×
Market median
-137% vs market
20122024
Debt / equity
0.77×
This company
0.62×
Market median
+24% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SS Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
BU Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
PA Management | Management | 2010 | — | — |
CD Management | Management | 2010 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2010 | — | — | |
| Chairman | 2010 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2010 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2010 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2013 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2016 | |
VÆKSTFONDEN | Company | 25.0% | 25.0% | 2012 |
EXPRES2ION HOLDING ApS | Company | 33.3% | 33.3% | 2015 |
AR CONSULT ApS | Company | 25.0% | 25.0% | 2015 |
AFFITECH A/S | Company | 20.0% | 20.0% | 2010 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
EXPRES2ION BIOTECHNOLOGIES ApS 
AdaptVac ApSBoard members of EXPRES2ION BIOTECHNOLOGIES ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Steen Søren Klysner | Chief Executive Officer | 0 companies |
| Bent Ulrich Frandsen | Chief Executive Officer | 0 companies |
| Peter Andreas Stakemann | Management | 0 companies |
| Charlotte Dyring | Management | 0 companies |
| Martin Welschof | Board of Directors | 0 companies |
| Martin Roland Jensen | Chairman | 0 companies |
| Jakob Ole Knudsen | Board of Directors | 0 companies |
| Allan Rosetzsky | Board of Directors | 0 companies |
| Sara Sande | Board of Directors | 0 companies |
| Willem Adriaan De Jongh | Board of Directors | 0 companies |
| Gitte Laurette Pedersen-Botero | Board of Directors | 0 companies |
| Karin Garre | Board of Directors | 0 companies |
| Jesper Roested | Board of Directors | 0 companies |
| Michel Jean Baijot | Board of Directors | 0 companies |
| Alexander R Duncan | Board of Directors | 0 companies |